Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for non-alcoholic steatohepatitis (NASH), a serious liver disease with significant unmet medical need. The company’s research and development efforts are centered on addressing the underlying causes and consequences of NASH, aiming to provide innovative treatment options for patients. Madrigal Pharmaceuticals is dedicated to advancing scientific understanding of liver diseases and developing therapies that can improve patient outcomes. The company operates within the biotechnology and pharmaceutical industries, contributing to advancements in the treatment of metabolic and liver-related disorders. Its commitment to research and clinical development positions it as a key player in the evolving landscape of NASH therapeutics.